Report to the U.S. Senate Health, Education, Labor and Pension (HELP) Committee: Prescription Drug Abuse Working Group

Similar documents
Florida s Roadmap to End its Prescription Drug Abuse Epidemic Florida Attorney General Pam Bondi One Page Summary

Building a Comprehensive, Community-driven Prevention Approach to the Opioid Crisis in Maine

Wednesday, June 21, Dear Chairmen and Ranking Members:

Submitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis

Performance of North Carolina's System for Monitoring Prescription Drug Abuse. Session Law , Section 12F.16.(q)

Combating the Opiate Crisis in Ohio

September 1, The Honorable Tom Price, MD Secretary Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201

BJA Harold Rogers PDMP National Meeting on Data Driven Multi-Disciplinary Approaches to Reducing Rx Abuse

Strategic Plan

Collaborative for Effective Prescription Opioid Policies

Cardinal Health s Commitment to Opioid Anti-Diversion, Education and Misuse Prevention

OPIOID WORKGROUP LEADERSHIP TEAM

Chairwoman Bono Mack, Vice-Chairwoman Blackburn, Ranking Member Butterfield and

September 22, National Association of Attorneys General 1850 M Street, NW, 12 th Floor Washington, DC Prescription Opioid Epidemic

OPIOID INITIATIVE SMART GOALS AND OBJECTIVES Four Pillar Approach

Strategies for Federal Agencies

Data-Driven Prevention Initiative

EXECUTIVE ORDER TAKING FURTHER ACTIONS TO ADDRESS THE OPIOID OVERDOSE CRISIS

ADVANCING WOMEN AND GIRLS, ONE CITY AT A TIME

Generation Rx: The Abuse of Prescription and Over-the-Counter Drugs

Successful Prevention Strategies to Address the Opioid Crises

The National Association of State Alcohol and Drug Abuse Directors (NASADAD) FY 2018 Appropriations

Tri-County Region Opioid Trends Clackamas, Multnomah, and Washington, Oregon. Executive Summary

ARIZONA SUBSTANCE ABUSE PARTNERSHIP Governor s Office for Children, Youth and Families

INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D

4/26/2018. Bureau of Professional Licensing. MAPS Updates & Opportunities. MAPS Background. Registration. MAPS Update

Donald K. Hallcom, Ph.D. March 13, 2014

COMMITMENT TO A TOBACCO ENDGAME IN ONTARIO

Community Response Addressing The Opioid Crisis. Leon, Wakulla, Gadsden, Franklin, Liberty, Jefferson, Madison and Taylor Counties

Meth and Opioid Abuse Prevention Efforts

Florida s Prescription Drug Diversion and Abuse Roadmap

Public Health Federal Funding Request to Address the Opioid Epidemic

HHSC LAR Request. Substance Abuse Disorder Coalition. Contact Person: Will Francis Members:

American Academy of Pain Medicine American Pain Society American Society of Anesthesiologists

National Strategies for Local Solutions

MANAGING THE COSTS OF THE OPIOID EPIDEMIC IN WISCONSIN. State Senator Alberta Darling

Data-Driven Multidisciplinary Approaches to Reduce Prescription Drug Abuse in Kentucky

Review of Controlled Drugs and Substances Act

Pennsylvania Prescription Drug Monitoring Program Trends,

Project Update: Comparing South Dakota Prescription Drug Monitoring Program Law Enforcement Profile Requests to Criminal History Data

Key Findings and Recommendations from the

Comprehensive Substance Abuse Strategic Action Plan

Implementing the 2017 President s Challenge: Primary, Secondary & Tertiary Prevention of Addiction & Substance Misuse

Taos Alive. Improving a Community in Pain By Julie Martinez CPS

SUBHEAD GOES HERE. Addressing Tennessee s Opioid Crisis. Natalie A. Tate, PharmD Vice President, Pharmacy

Prescription Opioid Overdose in Oregon: A public health perspective

COMMUNITY IN CRISIS Responding to the Opioid Epidemic in Southeastern North Carolina

STATE & FEDERAL EFFORTS TO COMBAT THE OPIOID EPIDEMIC & IMPACT ON COMPLIANCE PROGRAMS GRACE E. REBLING OSBORN MALEDON P.A.

1025 Connecticut Avenue NW, Suite 605 * Washington, DC * (202) * Fax: (202)

HHS Priorities and Actions to Support Treatment for Those with Opioid Use Disorder

Blue Cross of Idaho Addresses State s Opioid Issue

HOPE Agenda. Heroin, Opioid Prevention & Education WISCONSIN STATE REPRESENTATIVE JOHN NYGREN ASSEMBLY DISTRICT 89

Progress Report and 2018 Legislative Opportunities. Maine Opiate Collaborative Recommendations

Prescription Drug Take-Back Program Q s and A s

AHLA. X. Federal Enforcement of Fraud and Abuse Involving Opioid Abuse and Diversion

ASTHO President s Challenge 15 x 15: Reduce Prescription Drug

Combating Opiate Addiction

Opioid Overview Admiral Brett P. Giroir, M.D.

BJA COAP Category 6 Quarterly Webinar November 29, 2018

ADDRESSING THE OPIOID EPIDEMIC. Joint principles of the following organizations representing front-line physicians

Confronting the Opioid Crisis at the State Level

RX Drug Abuse Prevention in Nevada

Defying Gravity. Changing the conversation and landscape with prescription opioids

ADVOCACY IN ACTION TO ACHIEVE GENDER EQUALITY AND THE SUSTAINABLE DEVELOPMENT GOALS IN KENYA

Prescription Painkiller Abuse in Wisconsin Sharing a Dose of Reality. Brad Schimel Wisconsin Attorney General

Tom Williams, MD Chief Medical Officer Director of the Division of Public Health Nebraska Department of Health and Human Services

OPIOIDS IN AMERICA. A complex crisis. A comprehensive response.

On December 27, 2017, the Lieutenant Governor signed into law several new requirements

An Overview of the Government of Canada s Approach to Legalize, Regulate and Restrict Access to Cannabis. February 2018

Pennsylvania s Opioid Crisis: Data and Strategies to Combat It

Safe States Alliance 2018 Innovative Initiatives Finalist Summaries for Review

Prescription Monitoring Program Center for Excellence, Brandeis University. April 10-12, 2012 Walt Disney World Swan Resort

Opportunities for Engaging Partners to Prevent Opioid Overdose-related Deaths

Moving Towards a Continuum of Services. Plumas County Alcohol & Drug Strategic Planning Process DRAFT PLAN

C U S T O M E R D R I V E N. B U S I N E S S M I N D E D.

Comprehensive Opioid Abuse Program (COAP) Category 6 Grantees Call

White Paper on. Prescription Drug Abuse

FDA s Response to the Opioid Crisis and the FDA Safe Use Initiative

FACT SHEET: Federal Parity Task Force Takes Steps to Strengthen Insurance Coverage for Mental Health and Substance Use Disorders

THE FDA DRUG APPROVAL PROCESS Under the Federal Food, Drug, and Cosmetic (FD&C) Act, FDA is responsible for ensuring that all new drugs are safe and

PRESCRIPTION DRUG ABUSE: THE NATIONAL PERSPECTIVE

PDSA Delaware: A Data and Logic Model Driven Prescription Drug and Substance Abuse Change Approach for Delaware

Cannabis Legalization August 22, Ministry of Attorney General Ministry of Finance

But like others, we were initially fighting pill mills. Orange County worked to outlaw them and to provide resources for breaking opioid addiction.

Challenges for U.S. Attorneys Offices (USAO) in Opioid Cases

Coalition Strategies Across The Continuum of Care

COMBATING PENNSYLVANIA S OPIOID CRISIS PAID FOR BY SCOTT WAGNER FOR GOVERNOR

Informal meeting of the Justice and Home Affairs Ministers Sopot July 2011

Commonwealth of Kentucky NASCIO Recognition Awards Nomination Category: Data, Information and Knowledge Management. ekasper

LEADERSHIP PROFILE. Executive Director Gateway Center Atlanta, GA THE OPPORTUNITY

BREAKING THE CYCLE T H E O P I O I D E P I D E M I C I N A M E R I C A

A BluePrint for Ohio s Community Mental Health and Addiction System

Prescription Drug Abuse National Perspective

STATEMENT. of the. American Medical Association. for the Record. House Committee on Energy and Commerce

ILLICIT DRUG TRADE. Future-oriented policing projects

Law Enforcement and the Prescriber Enforcement Action Protocol

Opioid Abuse in Iowa Rx to Heroin. Iowa Governor s Office of Drug Control Policy January 2016

Prescription Drug Abuse Task Force Rx Report Card

PARTNERS FOR A HUNGER-FREE OREGON STRATEGIC PLAN Learn. Connect. Advocate. Partners for a Hunger-Free Oregon. Ending hunger before it begins.

Canadian Association of Chiefs of Police. Drug Abuse Committee. Annual Report

Transcription:

Report to the U.S. Senate Health, Education, Labor and Pension (HELP) Committee: Prescription Drug Abuse Working Group Introduction National Association of Attorneys General Substance Abuse Committee Florida Attorney General Pam Bondi (Co-Chair) June 25, 2014 State Attorneys General have been in our nation s forefront combating prescription drug diversion and abuse. Indeed, the States Attorneys General are in a unique position to engage law enforcement, public health, and community leaders to work together to end our nation s prescription drug abuse epidemic. State Attorneys General have fought back against this complex epidemic by initiating a broad based approach to shutting off the illicit supply of diverted pharmaceuticals through strong supply reduction operations, while simultaneously reducing demand for diverted pharmaceuticals through prescription drug abuse prevention programs. States with the best successes fighting pharmaceutical drug diversion have paired multi-agency and multi-jurisdictional law enforcement operations with the routine use of some form of a Prescription Drug Monitoring Program (PDMP) to fight the supply side of the equation, while the state s leadership cooperatively engages with the pharmaceutical industry and its public health community to change cultural norms regarding pharmaceutical drug use, thereby attacking the demand side of the equation. Outline This report is organized as follows: 1. Prevention a. The Partnership at drugfree.org b. Prescription Drug Take Back Day Events 2. Law Enforcement a. Coordinating law enforcement and health regulators to work together b. Creating state-level Drug Enforcement Strike Forces (or task forces) c. Sustaining state-level Prescription Drug Monitoring Programs (PDMP) 3. Drug Exposed Newborns a. State-level responses to prescription drug abuse and newborns 4. Policy Recommendations a. Sustain Federal funding for state operated drug courts. b. Continue funding for the Drug-Free Communities program. c. Prioritize National Institute of Drug Abuse (NIDA) funding to research effective treatment protocols for Neonatal Abstinence Syndrome. d. Increase funding for the Bureau of Justice Assistance s Harold Rogers Prescription Drug Monitoring Program (HRPDMP) and also allow funds to be more flexible to the needs of all state PDMPs. e. Ensure continued DEA support for local Prescription Drug Take-Back Day events and support the rapid adoption of DEA s new prescription drug disposal rule. f. Maintain Federal funding supporting state Fusion Centers to help gather, decipher and disseminate actionable drug intelligence. 1

g. Embrace a more open and transparent system to inform the public regarding annual opioid production levels for pharmaceutical companies, by enabling state, local and public input to the decision making process. 1. Prevention The most cost-effective way to fight prescription drug abuse is to prevent it from happening in the first place. Since addiction is a preventable disease, countering widespread lack of awareness as to the dangers of prescription drug abuse has been a priority of the State Attorneys General. The fundamental goal of prevention education must be to shift people s perceptions and attitudes regarding the harm that comes from misusing prescription drugs. To that end, the States Attorneys General have been working with The Partnership at DrugFree.org (http://www.drugfree.org) to begin changing cultural norms around the prescribing, dispensing and use of prescription drugs. This nationwide initiative involves prevention messaging campaigns, and advocating for the safe and secure disposal of unused/expired prescription drugs. The family medicine cabinet is the largest source for diverted prescription drugs in our nation. The safe disposal of expired, unused or unnecessary prescription drugs is therefore a key component in the States Attorneys General efforts to curb prescription drug abuse. The Drug Enforcement Agency (DEA) deserves special praise fighting this type of diversion by hosting Prescription Drug Take-Back Day events with local law enforcement. National Prescription Drug Take-Back Days aims to provide a safe, secure, and environmentally responsible means of disposing of prescription drugs, while also educating the general public about the potential for abuse and trafficking of medications. For instance, on April 26 th, 4,423 state, local and tribal law enforcement partners collected 780,158 pounds (390 tons) of pills at 6,072 collection sites. When added to amounts collected at previous DEA-coordinated Take-Back events, some 4.1 million pounds (2,123 tons) of prescription medications have been removed from circulation. Take-Back Day events are a step in the right direction, but are equivalent to Recycling Day programs of the 1970s. It may be hard to believe for some people under the age of 40, but many communities had to hold special events so families could turn-in their aluminum cans and newsprint to one centrally located recycling center. Today, by contrast, we have convenient collection receptacles at home, and most publicly located garbage cans allow people to recycle their plastic bottle or aluminum can. A great example of expanded safe disposal sites is now occurring in New Jersey with Project Medicine Drop. Launched in November 2011, Project Medicine Drop allows consumers to dispose of unused or expired prescription or over-the-counter medication at drop box locations within participating police departments. The drop boxes are similar to a post office mail box, and are installed indoors, affixed to the floor or wall in a secure area, but still accessible to the general public. Currently, New Jersey has over 70 permanent drop box locations, with another 40 police departments joining the program later this year. Our nation must move quickly to expand the venues where people can turn-in unused medications, instead of having to wait for an occasional Take-Back event. An important step forward in this effort is to adopt federal rules (FR Doc. 2012-30699)-proposed by the DEA-that will allow for more take-back events, prescription drug mail-back programs and the permitting of collection receptacles at secure locations; Congress should support the timely adoption of these new rules. 2

2. Law Enforcement Federal, state and local teamwork is necessary to shutdown pill mills, because only a combination of administrative, civil and criminal sanctions will prevail against what has become an extremely lucrative and adaptive business. A key approach for these multi-disciplinary teams is determining which pill mill clinics are unlicensed or improperly operated. Because all states have laws and regulations for determining whether healthcare practitioners meet minimum licensure requirements, state medical licensing agencies are therefore well suited for a myriad of important counter-pill mill activities, such as: evaluating the credentials of pain management clinics for licensure; issuing and renewing licenses; analyzing and investigating complaints; conducting routine clinic inspections; and very importantly, assisting in prosecuting practice act violations as well as providing the public the credentials and discipline history of pain clinic licensees. Perhaps the most critical function a state health agency can play as part of the enforcement process is in issuing emergency suspension orders to shut down both the pill mills masquerading as pain management clinics and the unscrupulous doctors either operating or staffing these clinics. Florida s Department of Health, for example, has used its emergency orders tool to great effect in recent years. Indeed, Florida s DOH has played a pivotal role in the all hands approach Florida employed to turn the tide against pill mills and bad docs, greatly reducing the effects of prescription drug diversion and abuse in this hard hit state (chart I). Chart I 3,000 2,500 2,000 1,500 1,000 Total Rx Drug Overdose Deaths: Florida 2003-2012 2,710 2,488 2,539 2,184 2,002 2,090 1,720 1,530 1,433 1,234 500 0 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 Another major step forward in many states fight to reduce the size and scale of the prescription drug abuse epidemic has been the creation of Regional Drug Enforcement Strike Forces (or task forces) to better share investigatory resources and expertise across a wide spectrum of law enforcement and health care regulatory agencies. This team approach has been largely focused on combating major pharmaceutical drug diverters, such as: diversion operations fronted by healthcare practitioners; organized groups of pill seeking patients; pain management clinics; unscrupulous pharmacies; and, increasingly, traditional drug-trafficking organizations seeking a share of this lucrative black market. Critical to any long term sustained success in such broad, multi-agency efforts has been the development of agreements covering roles, asset sharing and investigative reimbursement. A 3

good illustration of this cooperation is state-level law enforcement agencies providing sworn, analytical and administrative personnel to strengthen the intelligence gathering capabilities of these strike forces, while simultaneously encouraging other state and local agencies to participate in and contribute funds and personnel to these complex investigations. Because shutting down pill mills often entails complex investigations, state operated Prescription Drug Monitoring Programs (PDMP) is another key tool aiding in these investigations. While PDMPs are not designed nor intended to be a means to target individuals, they are an outstanding forensic tool for assisting ongoing criminal investigations into pharmaceutical diversion. PDMPs also play an important role in improving patient standard-of-care by providing doctors with their patient s prescription history, and PDMPs can even reduce prescription drug diversion at the retail point-of-sales level. Ultimately, PDMPs save lives and taxpayers money. Encouragingly, every state except Missouri now either has or is rapidly implementing a PDMP. 3. Rx Drug Abuse & Newborns Abuse and neglect of children is one of the most insidious ways prescription drug addiction affects our communities. Hospitals in states plagued by high prescription drug abuse rates now report dramatic increases in the number of newborns being treated for Neonatal Abstinence Syndrome (NAS). NAS refers to a group of medical complications associated with the withdrawal process newborns typically experience after birth if their mothers used illicit drugs or abused prescription drugs. NAS babies are born in withdrawal, suffering from symptoms such as tremors, seizures, abdominal pain, incessant crying, and rapid breathing. Many states are now creating state-level responses to NAS. For example, Florida Attorney General Pam Bondi worked with her Legislature in 2012 to establish the Statewide Task Force on Prescription Drug Abuse and Newborns. This 15-member Task Force examined the extent of prescription drug abuse among expectant mothers, as well as the costs of caring for babies with NAS, the long-term effects of the syndrome, and prevention strategies. The Task Force completed its study and published 15 policy recommendations last February a full year ahead of schedule. One of the Florida task force s policy recommendations was to create a statewide public awareness initiative. General Bondi partnered with the Florida Departments of Children & Families and Health to launch the Born Drug-Free Florida campaign. The slogan Your baby s life shouldn t begin with detox, was seen and heard throughout Florida. This campaign also established a website with important information for pregnant women, including how to take the first steps in getting help. One important outcome from this prevention campaign has been the creation of a helpline for women. This hotline screens callers, refers them to appropriate facilities in their area and provides other informational resources. Since its launch in June 2013, the hotline has helped at least 140 pregnant women begin substance abuse treatment. 4

An additional task force recommendation was to substantially enhance substance abuse treatment for pregnant women and mothers with children. Thanks to the Florida Legislature s leadership, the Department of Children & Families received $8.9M in 2013 for new substance abuse treatment funding for this critically important population. In 2014, the Florida Legislature added an additional $1M-for a new baseline total of $10M-and, crucially, made this funding an annually recurring budget line item. This new funding will allow treatment providers to offer the specialized care pregnant woman or mothers with children need during their recovery process. 4. NAAG Substance Abuse Committee s Recommendations Sustain Federal funding for state operated drug courts. o Drug Courts and Veterans Treatment Courts save money and cut crime. In 2011, the U.S. Government Accountability Office confirmed these results, and concluded that Drug Courts reduce crime by up to 58%. Congress investment in these courts will save money, cut crime, and serve veterans in need. o On May 30th, the House of Representatives approved $59 million for Drug Courts and Veterans Treatment Courts at the Department of Justice. $44 million for the Drug Court Discretionary Grant Program, Bureau of Justice Assistance, Department of Justice $15 million for Veterans Treatment Courts, Bureau of Justice Assistance, Department of Justice Continue funding for the Drug-Free Communities (DFC) program. o Drug-Free Communities is a collaborative effort between the Office of National Drug Control Policy and the Substance Abuse and Mental Health Services Administration. Coalition training and technical assistance is provided by Community Anti-Drug Coalitions of America. o The DFC program is the nation s largest federally-funded prevention program, and has a sustained record of effectiveness. o DFC grantees have reduced drug use and abuse in communities throughout the country to levels lower than national averages because they are organized, data driven and take a comprehensive, multi-sector approach to solving and addressing drug issues. Prioritize National Institute of Drug Abuse (NIDA) funding to research effective treatment protocols for Neonatal Abstinence Syndrome. o Doctors and hospitals are interested in researching which NAS treatment protocols are the most effective, as well as finding methods to reduce the amount of time a drug exposed newborn must stay in a Neonatal Intensive Care Unit (NICU). o Since a majority of the costs in treating NAS are concentrated in NICUs, finding the safest and most effective treatment for newborns can be particularly cost-effective. Increase funding for the Bureau of Justice Assistance s Harold Rogers Prescription Drug Monitoring Program (HRPDMP), and enable these funds to be used more flexibly by state PDMPs. o The HRPDMP funds have been focused on supporting data sharing efforts among state PDMPs. However, funding for this program should become more flexible so states can also apply for funding enhancements to improve medical personnel s timely use of the system or to improve law enforcement s ability to utilize the data to reduce diversion and abuse. 5

o Inter-state data sharing is not popular in all states; HRPDMP funds should therefore account for this reality by allowing these particular states to use their HRPDMP funds strictly for internal enhancements. Ensure continued DEA support for local Prescription Drug Take-Back Day events and support the rapid adoption of DEA s new prescription drug disposal rule. o Typically, local communities cannot hold Take-Back events without the DEA s financial support. Until a regulatory framework is in place (see next bullet below) to more easily allow consumers to dispose of their unused, expired or unnecessary medications, the DEA will need to continue to support local communities in the safe collection and disposal of prescription drugs. o Congress should support the adoption of DEA s rule to increase the safe disposal of used/expired prescription drugs. These new regulations would implement the Secure and Responsible Drug Disposal Act of 2010 by expanding the options available to collect controlled substances from ultimate users for purposes of disposal to include: Take-back events, mail-back programs, and collection receptacle locations http://www.deadiversion.usdoj.gov/fed_regs/rules/2012/fr1221_8.htm Maintain Federal funding supporting state Fusion Centers so as to continue to help the states gather, decipher and disseminate actionable drug intelligence. o Fusion Centers represent one of the most important recent developments in U.S. law enforcement. A fusion center processes a wide range of raw data and finished intelligence from disparate sources and agencies and then fuses this information for evaluation, analysis, and dissemination back to the field. o Fusion centers leverage information technologies to better manage the huge daily flood of data that threatens to inundate already overworked local law enforcement agencies. o State-operated Fusion Centers are supported in part by funding from the Department of Homeland Security s Homeland Security Grant Program (HSGP) and the Department of Justice s Justice Assistance Grants (JAG). Embrace a more open and transparent system to inform the public regarding annual opioid production levels for pharmaceutical companies, by enabling state, local and public input to the decision making process. o It is not widely known that the DEA s Office of Diversion Control has the power to set annual production totals for a particular drug. o Creating an open and transparent approval system will better inform the public and create improved public health outcomes because there will be a more holistic and informed production quota decision-making process. 6